GlassScriptPhysician profile
Michael Joseph Obrien
NPI 1386628170
$13,698.09
in general payments reported to CMS, 2019-2025
62 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,273 · 2020: $1,313 · 2021: $1,824 · 2022: $1,843 · 2023: $1,530 · 2024: $4,591 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,144 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,144.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $3,361.90 | 2024 | Healicoil |
| Abbvie INC. | $1,038.93 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $999.07 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $762.31 | 2019-2023 | |
| Amgen INC. | $643.50 | 2019-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $575.96 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $507.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $468.38 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.24 | 2019-2025 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $396.45 | 2019-2025 | Ajovy, Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $318.51 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.08 | 2020-2025 | Jardiance, Tradjenta, Ofev |
| Janssen Pharmaceuticals, INC | $262.74 | 2019-2024 | Xarelto |
| Allergan, INC. | $215.65 | 2019-2020 | |
| Corium, LLC | $214.01 | 2022-2023 | Azstarys |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.